What are the advantages of Yiluake Tablets (Qixinke) in treating lung cancer?

The advantages of Yiruake Tablets (Qixinke) in the treatment of lung cancer mainly include improved progression-free survival, improved objective response rate, improved intracranial objective response rate, new treatment options, good safety and tolerability, first-line treatment, etc. It needs to be used under the guidance of a physician with experience in treatment.

Advantages of treating lung cancer

1. Improve progression-free survival: Compared with crizotinib, Iluak Tablets can significantly improve the progression-free survival of patients. In clinical trials, the median PFS in the Iluaq group was significantly longer than that in the crizotinib group, indicating that patients had a lower risk of disease progression when receiving Iluaq treatment.

2. Improve the objective response rate: Yiruake tablets have shown a higher objective response rate in clinical studies, which means that more patients have reduced or disappeared tumor size after receiving treatment.

3. Improve the intracranial objective response rate: For patients with brain metastases, Yiruake Tablets can provide a higher intracranial objective response rate, which is particularly important for improving the prognosis of these patients.

4. New treatment options: Yiruak Tablets can effectively inhibit the ALK kinase activity of ALK inhibitor-resistant mutations. For patients who have developed resistance to first-generation ALK inhibitors, Yiluak Tablets provides a new treatment option.

5. Good safety and tolerability: Yiruak tablets have shown good safety and tolerability in clinical trials, which is an important consideration for patients on long-term treatment.

6. First-line treatment: The phase III clinical study of Iluak Tablets has completed the interim analysis, showing that compared with crizotinib, it has significant advantages in the first-line treatment of patients with ALK-positive NSCLC, which may mean that Iluak Tablets will become a new first-line treatment option for patients with ALK-positive NSCLC in the future.

Efficacy of Yiruake Tablets (Qixinke) in the treatment of lung cancer

Research background

Iluake Tablets is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here, we report results from a single-arm phase II study (INTELLECT) of the efficacy and safety of iruplinalkib in patients with ALK-positive, crizotinib-resistant advanced non-small cell lung cancer (NSCLC).

Research Methods

Patients with ALK-positive crizotinib-resistant advanced NSCLC aged ≥18 years and with Eastern Cooperative Oncology Group performance status 0-2 are eligible. Patients received Iluac tablets 180 mg once daily for a 21-day cycle, and 60 mg orally once daily during a 7-day run-in period.

Research results

From August 7, 2019 to October 30, 2020, a total of 146 patients were included, with a median follow-up time of 18.2 months. The ORR and disease control rate (DCR) assessed by IRC were 69.9% and 96.6%, respectively. The ORR and DCR assessed by the investigators were 63% and 94.5% respectively.

The median duration of response and progression-free survival (same as the median time to progression) assessed by the researchers were 13.2 months and 14.5 months respectively, and the corresponding IRC assessment results were 14.4 months and 19.8 months respectively. The investigators evaluated intracranial ORR to be 46% in patients with central nervous system metastases and 64% in patients with measurable intracranial disease. Overall survival data are immature.

Treatment-related adverse events occurred in 136/146 (93.2%) patients. The most common TRAEs were increased aspartate aminotransferase, increased alanine aminotransferase, and increased blood creatine phosphokinase. There were no increased safety risks in the iluaq arm compared with the crizotinib arm.

Research conclusion

In this study, Iluak tablets showed good efficacy and controllable safety in patients with ALK-positive, crizotinib-resistant advanced non-small cell lung cancer, and can become a new treatment option for this patient group.

The price of Yiruake Tablets (Qixinke)

Currently, we know that the reference price of the cheaper Yiluake Tablets is about 3960$-4500$ per box. The price will also change due to various factors.

Summary

Iluak tablets have shown significant efficacy advantages in the treatment of ALK-positive non-small cell lung cancer, especially in terms of progression-free survival, objective response rate and effective overcoming of drug resistance.

Recommended hot articles: